China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing for its in-house developed Category 1 biological product, Xeligekimab, for the treatment of moderate to severe plaque psoriasis has been accepted for review. This development marks a significant step forward for the company and the potential treatment option for patients suffering from psoriasis.
Xeligekimab’s Mechanism of Action and Clinical Progress
Xeligekimab is the first anti-IL-17 antibody to enter Phase III trials in China. Pre-clinical studies have demonstrated that Xeligekimab can selectively bind to IL-17A, inhibiting the downstream signal transduction of IL-17RA and suppressing IL-17A-induced inflammatory reactions. The drug’s efficacy is reportedly comparable to that of secukinumab, a known anti-IL-17 therapy.
Implications for Psoriasis Treatment
The acceptance of Xeligekimab’s market approval filing for review is an important regulatory milestone for Chongqing Genrix Biopharmaceutical. If approved, Xeligekimab could offer a new treatment option for patients with moderate to severe plaque psoriasis, contributing to the expanding therapeutic landscape for this chronic skin condition.-Fineline Info & Tech
